CliffBio
small molecule

DOTAREM

GADOTERATE MEGLUMINE

Loss of exclusivity—loss of exclusivity
CompanyGuerbet →See this company's full patent-cliff portfolio

Drug detail

Brand nameDOTAREM
Active ingredientGADOTERATE MEGLUMINE
Strength7.538GM/20ML (376.9MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMarch 2013
Marketing statusRX

More from Guerbet

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DOTAREM patent cliff — loss of exclusivity — | CliffBio